

A' 3.12.15  
cont.

wherein said packaging material comprises a label or a written material which indicates that the compound identified in claim 10 can or should be used for preventing and/or treating dysuria.--

### SUPPORT FOR THE AMENDMENT

Claims 10-20 find support in the specification at pages 32-37 that describe the compounds of formulas (IV), (V), (VI), (VII) and (VIII). Prodrugs are described on page 48, lines 1-2 of the specification. Accordingly, the Applicants do not believe that any new matter has been added.

### REMARKS


Claims 1-20 are pending.

### CONCLUSION

Applicants respectfully submit that the claims are now in condition for early examination on the merits.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No.: 24,618



22850

PHONE NO.: (703) 413-3000  
FAX NO.: (703) 413-2220

Thomas M. Cunningham  
Registration No.: 45,394



.219501US-0 CONT

**Marked-Up Copy**

Serial No: 10/074,020

Amendment Filed Herewith

**IN THE CLAIMS**

Add new claims 10-20.

--10-20. (New)--

